Exhibit 99.1





|Wells Fargo Securities2011 Healthcare ConferenceDoug GodshallChief Executive Officer and PresidentJune 22, 2011
|---------------------------------------------------------------------------------------------------------------



---



##### 






|Safe Harbor Statement

Forward-Looking Statements This presentation contains forward-looking statements that are based on our management's beliefs, assumptions and expectations and
on information currently available to our management. Generally, you can identify forward-looking statements by terms such as "may,"
"will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar
expressions intended to identify forward-looking statements, which generally are not historical in nature. All statements that address
operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements,
including without limitation, our expectations regarding (a) regulatory submissions and approvals; (b) our clinical trials, including
enrollment in our clinical trials and estimates of regulatory filing dates;  (c) our intellectual property position;  (d) our perceived ability to
develop, receive approval for and commercialize our existing and new products;  (e) our expected lead times for achieving milestones
and (f) our estimates regarding our preliminary financial results.



The forward-looking statements reflect our current view about future events and are subject to risks, uncertainties and assumptions.
Accordingly, you should not place undue reliance on our forward-looking statements.  Except as required by law, we do not assume any
obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
We may not actually achieve the plans, projections or expectations disclosed in our forward-looking statements, and actual results,
developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are
subject to a number of risks and uncertainties, including without limitation those described in Part I, "Item 1A. Risk Factors" of our Form
10-K for the year ended December 31, 2010 and subsequent filed reports.   For instance, the following important factors could prevent us from achieving our goals and cause the assumptions underlying the
forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward looking
statements: (a) inability to fund ongoing operations, including raising additional capital to support further development and growth; (b)
inability to recruit, retain and motivate appropriately qualified employees; (c)  unsatisfactory or uncompetitive clinical outcomes  for our
products  (e.g. high stroke, device failure or adverse event rates); (d) lack of physician acceptance or adoption of our products; and, (e)
inability to receive and maintain regulatory approvals and consents (e.g. ISO, FDA etc). Additional information concerning our risk
factors and uncertainties is contained in our filings with the SEC and ASX.

CAUTION:  Investigational device. Limited by United States law to investigational use.
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Heart Failure

A degenerative and terminal diseaseAffects over 20 million people globally
(5+ million in the US)1 million new cases diagnosed every year300,000 deaths per year in the US (1 in 8 deaths)At least 1 million patients in NYHA Class IV,
the end-stage of the diseaseIn the US, heart failure represents Medicare's
greatest area of spendingEstimated annual cost of $37B  1.1M hospital discharges in 2006; up 171% since 1979VADS emerging as only viable option for
many with late stage disease


Source: Circulation, AHA update, January 2009Heart Failure Society of America / NHLBI
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|1st Qtr    2nd Qtr
    1980    401    350
        423    345
        439    330
        464    310
        531    305
        557    300
        582    295
        605    290
        634    285
        643    270
    1990    701    265
        764    255
        822    250
        875    240
        874    235
        872    235
        870    220
        957    210
        978    205
        962    200
    2000    999    189
        995    178
        970    171
    2003    1037


Coronary Deaths

Coronary deaths are down by half

But heart failure has almost tripled
(CHART)

Heart Failure

Source:  National Hospital Discharge Survey data. Centers for Disease Control and Prevention/National Center for Health Statistics and National Heart, Lung, and Blood Institute.

Enhanced survival in other CV diseases leads to expansion of HF Population

Heart Failure: The Final Cardiovascular Disease

CAUTION:  Investigational device. Limited by United States law to investigational use.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Global VAD Market Acceleration Continues

* Industry reports, HeartWare estimates, Thoratec estimates

CAUTION:  Investigational device. Limited by United States law to investigational use.
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|HeartWare(r) Ventricular Assist System

HVAD(r) miniaturized implantable blood pump Pericardial placement - no pump pocketProvides up to 10 L/min of flowCentrifugal design, continuous flowHybrid magnetic / hydrodynamic impeller
suspensionOptimizes flow, pump surface washing, and
hemocompatibilityThin (4.2 mm), flexible driveline with fatigue
resistant cablesZero cable fractures
CAUTION:  Investigational device. Limited by United States law to investigational use.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Design Enables Pericardial Placement

Design benefitsEfficient powerWide blade impeller
enables low fluid stressUser friendly tools may
decrease surgery time
Pericardial benefitsNo abdominal surgeryNo pump pocketPotential to expand pool of
treatable patients

Fundamental attributes resonating globally

CAUTION:  Investigational device. Limited by United States law to investigational use.
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Simple, Elegant Fluid Dynamics


Secondary flow path
Washes underside and
center post regions

Tertiary flow pathProvides fluid "cushion";
washes thrust bearings

Primary flow pathWashes flow channels
and immediately enters
outflow graft

Levitated impeller; Free from
mechanical contact points

CAUTION:  Investigational device. Limited by United States law to investigational use.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Leading a Small Revolution

More than 1,000 HeartWare
Ventricular Assist System
Implants GloballyHeartWare has grown to
260+ employees todayHeadquarters near Boston,
Massachusetts (Framingham)Manufacturing in Miami,
Florida Development and operations
facility in Kirrawee, NSW

CAUTION:  Investigational device. Limited by United States law to investigational use.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|HeartWare: Strengthened Base for Future Growth

Maturing commercial organization in EuropeBolstered manufacturing to accommodate
clinical ramp in USAugmented field team to educate and service
larger commercial and clinical customer basePositioning organization for FDA audit process
and US launch preparationExpanded R&D capabilities to accelerate
pipelineExpanding Clinical team to manage expanding
trial activities
CAUTION:  Investigational device. Limited by United States law to investigational use.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Geographic revenue breakdown

Geographic revenue breakdown
|----------------------------------------------------------



---



##### 






|International Rollout Gaining Momentum

CAUTION:  Investigational device. Limited by United States law to investigational use.




















































































































































































































































International market growth robustExpanding global acceptance56 customers, 18 countriesReported 134 units sold in Q1Follows 112 in Q3; 161 in Q4Expanded capabilities to capitalize on growing
demand; 14 employees France reimbursement approved; pricing expected in
H1 '11Belgian reimbursement H1 '11Primary focus remains on optimizing patient outcomes

As of 5/5/11
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Clinical and regulatory tracking - HVAD

United States - Bridge-to-Transplant    United States - Continued Access for BTTUnited States - Destination Therapy
DT IDE
Approved by
FDA June 2010

First implants
Aug 2010

Began April 2010; Two 54-patient allotments complete; Third enrolling

CAUTION:  Investigational device. Limited by United States law to investigational use.

46 of 50 sites
initiated
(as of 5 / 5 / 11)

    United States - REVIVE-IT (awarded; protocol finalization)
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Two Largest VAD Trials

ADVANCEBridge-to-Transplant140 patients at 30 sites6-month follow up completed
8/2010Control: contemporaneous
patients in INTERMACS
registryPMA submitted 12/27/10Met primary endpointContinued Access Protocol in
place29 of 30 sites initiated in CAP94
ENDURANCEDestination Therapy450 patients at up to 50
centers; randomized 2:1121 patients now enrolledControl: commercially
approved DT LVAD2-year follow upSuccess: alive, on original
device w/o major strokeProjecting 300 patients
enrolled Q4 '11 and 450 in
H1 '12

As of 5/5/11

CAUTION:  Investigational device. Limited by United States law to investigational use.
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|94% survival at 180 days, 91% projected survival at 360 daysHVAD pump demonstrated non-inferiority to contemporaneously
implanted, commercially available ventricular assist devicesImplantation of the HVAD pump was associated with a 92%
probability of success at 180 daysAdverse event profile in line with our expectationsData demonstrated marked improvement in functional capacity and
quality of life measurements from patient baseline

ADVANCE BTT Trial: Summary of Results

CAUTION:  Investigational device. Limited by United States law to investigational use.

Data cutoff Aug. 23, 2010;  89.45 patient years on support
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Days Post Implant

Proportion of Patients

 62.8% Alive

 29.2% Transplant

 3.6% Death

 4.4% Device Exchange

92.0% Transplant or Alive

ADVANCE Trial Treatment Group Outcomes (Per Protocol Population)
   Patients at Risk   137   125   104   86   58   31   22

NOTE: Original device in
place for all outcomes

CAUTION:  Investigational device. Limited by United States law to investigational use.
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Applying Seattle Heart Failure Model to ADVANCE

Figure 1: SHFM Estimated Survival

Wayne C. Levy, et al, ISHLT 2011
|--------------------------------------------------------------------------------------------------------------------



---



##### 






|Overall Survival Comparison: SHFM vs. ADVANCE

Figure 1: SHFM Estimated Survival

Figure 1: SHFM Estimated Survival

Wayne C. Levy, et al, ISHLT 2011
|-----------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|ADVANCE and CAP Update

June 21, 2011
|-------------------------------------



---



##### 






|ADVANCE:140 patients enrolled - last implant Feb 28, 201052 patients remain on pump (37%) CAP:144 patients enrolled111 remain on pump (77%)BTT / CAP combined: 284 enrolled in both trials for 217 patient-years
of support
Current Status of ADVANCE and CAP
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Methodology and Objective

Event rates for device exchange for thrombus post
discharge, GI bleeding and strokes were compared by
time on pump for the following periods:ADVANCE and CAP combined to June 14, 2011 (i.e. the
current overall rates): 284 patients for 217 patient-yearsADVANCE and CAP from March 14th to June 14th: 163 patients for 40 patient-yearsObjective: Identify impact of changes to antiplatelet
approach (325 mg ASA), if any, and confirm that initial
results are as anticipated
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Distribution of Time on Pump

Total = 163 patients on HVAD support during the period March 14 - June 14 Majority of patients confirmed to be on 325 mg
(CHART)

CAUTION:  Investigational device. Limited by United States law to investigational use.
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|(CHART)

Exchange Rates for Suspected Thrombus

 One exchange for thrombus in 163 patients March 14 - June 14 Resembles ISHLT finding of 1 exchange in 73 patient years with 325 mg ASA 217 patient years in BTT/CAP and 40 from March 14 - June 14

CAUTION:  Investigational device. Limited by United States law to investigational use.
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|GI Bleeding
(CHART)

CAUTION:  Investigational device. Limited by United States law to investigational use.
|-----------------------------------------------------------------------------------------------------------



---



##### 






|Stroke Rates Total Trial vs. Recent Quarter

Stroke Rates Total Trial vs. Recent Quarter

CAUTION:  Investigational device. Limited by United States law to investigational use.
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|284 patients have been enrolled in ADVANCE and CAP for more
than 217 patient-years of supportSurvival has been consistently high in all trials to dateSepsis and driveline infections are notably infrequentGI bleeding rate and bleeding in general remain low Full dose aspirin (325 mg) appears to be an ingredient for
decreasing risk of pump thrombus without evidence of increased
bleeding or hemorrhagic stroke (vs. 0-162 mg)

Investigator Update Summary

CAUTION:  Investigational device. Limited by United States law to investigational use.
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Development Priorities for 2011

"Evergreen" HVADEnhancements to pump and algorithmsIntroduce new tools to improve implantUpgrade patient accessoriesDrive MVAD to First-in-ManMultiple versions under wayDesign for AE reduction to expand treatable
populationAccelerate NG ElectronicsNext Generation ControllerRamping TETS investmentExpanding development on multiple programs
Focus areas for accelerated investment

CAUTION:  Investigational device. Limited by United States law to investigational use.
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Evergreen HVAD - Enhancements for Next 12 Months

Improved
patient packs

Redesigned
product packaging

New Apical Coring Tool

Sintered inflow cannula

Revised controller with
updated software

Shower bag

CAUTION:  Investigational device. Limited by United States law to investigational use.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Sintered  Inflow

Sintered  Inflow

CAUTION:  Investigational device. Limited by United States law to investigational use.

FDA approved sintering
for both BTT/CAP and
DT studies in AprilFirst sintered pump
implants in May34 sites have already
received IRB approval for
sintered pumpsBSI approved sintered
pumps as supplement to
CE Mark in April;
Shipping commenced
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Compelling Pipeline - Miniaturized VAD design

Expanded portfolio of MVAD designsExploring new patient populationsMore than 75 animal studies conducted
to date; strong early resultsGLP animal studies started Q1 '11First-in-man studies Q1 '12Wide blade impeller with hybrid
suspension allows significant
miniaturizationUltra-thin driveline Simplified manufacturingPartial or full support attainable; Wear-
less impeller suspensionAll versions can eliminate sternotomy
Designed to decrease invasiveness without decreasing efficacy

CAUTION:  Investigational device. Limited by United States law to investigational use.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Selected Financial Snapshot

RevenueQ1 2011 revenues $18M; up 68% from Q1 in 20102010 revenues of $55M; up 128% from $24M 2009
(CHART)

$ Millions

Implant rate and growth likely to be variable in 2011Capital structureTreasury exceeds $214M in capital at 3/31Convertible debt $143M ($100 conversion price)Stock on Issue: 13.9M shares
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Another Busy Year

Initiation of MVAD GLP animal studies in Q1 2011 ^Secure reimbursement and launch HVAD in FrancePreparation for PMA audit; potential advisory committee panelISHLT presentation of ADVANCE trial and CAP data ^Drive enrollment in DT and CAPPublication of ADVANCE dataEnroll 300th patient in ENDURANCE DT study by year-endCrystallize BiVad clinical / regulatory pathRoll out multiple HVAD product enhancements ^Accelerate electronics portfolioCommence human clinical studies for MVADPrepare for US launch
CAUTION:  Investigational device. Limited by United States law to investigational use.
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 






|Leading a Small Revolution

CAUTION:  Investigational device. Limited by United States law to investigational use.
|------------------------------------------------------------------------------------------------------------------